Fis1 Inhibitors
Fis1 inhibitors belong to a distinct chemical class that has garnered considerable attention in the field of molecular biology and cellular research. Fis1, or Mitochondrial Fission 1 protein, is a pivotal component of the mitochondrial fission machinery, playing a crucial role in regulating the dynamic process of mitochondrial fission – the division of mitochondria into smaller units. The inhibition of Fis1 serves as a promising avenue for investigating the fundamental mechanisms governing mitochondrial dynamics and cellular homeostasis. These inhibitors are meticulously designed compounds that target the Fis1 protein, impeding its functional activity and disrupting its involvement in mitochondrial fission. Through precise molecular interactions, these compounds modulate the intricate protein-protein interactions and signaling pathways that drive mitochondrial fission. By influencing Fis1, these inhibitors not only offer insights into the mechanistic intricacies of mitochondrial dynamics but also hold the ability to uncover broader implications for cellular processes that rely on well-balanced mitochondrial morphology.
The development and utilization of Fis1 inhibitors contribute to expanding the understanding of mitochondrial biology and its implications for cellular health. Researchers and scientists have recognized the significance of dissecting the role of Fis1 in mitochondrial dynamics. Through the targeted inhibition of Fis1, researchers can delve into unraveling the complexities of cellular responses to various stimuli and conditions, shedding light on the broader context of organelle dynamics and cellular adaptation. As investigations into Fis1 inhibitors continue, they offer a remarkable toolset for exploring the intricate interplay between molecular components within cells, ultimately deepening our comprehension of cellular function and its underlying regulatory mechanisms.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib is a covalent inhibitor of Bruton's tyrosine kinase (BTK), an enzyme crucial for B-cell receptor signaling. It forms a covalent bond with a cysteine residue, preventing BTK activation and thereby suppressing B-cell proliferation and survival. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits the tyrosine kinase activity of the BCR-ABL fusion protein, an abnormal kinase linked to chronic myeloid leukemia (CML). It competitively binds to the ATP-binding site of the kinase, preventing phosphorylation of substrates and inhibiting cancer cell growth. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It competes with ATP for binding to EGFR, inhibiting its autophosphorylation and downstream signaling pathways. This leads to the suppression of cell proliferation and angiogenesis in cancers. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-targeted kinase inhibitor that inhibits RAF kinases and receptor tyrosine kinases (VEGFR, PDGFR, c-KIT). It disrupts cell proliferation and angiogenesis signaling, hindering tumor growth and progression. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib inhibits Janus kinases (JAK1 and JAK2), which are involved in cytokine signaling. By inhibiting JAKs, it interferes with downstream STAT activation, leading to reduced inflammation and cell proliferation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR and HER2. It binds to the ATP-binding pocket of the kinases, blocking receptor autophosphorylation and downstream signaling pathways. This results in reduced cell growth and survival in HER2-positive cancers. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Vemurafenib inhibits mutated BRAF kinase in melanomas with the V600E mutation. By binding to the ATP-binding site, it prevents kinase activity and downstream MAPK pathway activation, leading to reduced cell proliferation and increased apoptosis in BRAF-mutated cancers. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It disrupts the cell cycle progression by blocking the activity of CDK4/6, leading to G1 phase arrest and reduced cell proliferation in hormone receptor-positive breast cancers. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Alectinib targets anaplastic lymphoma kinase (ALK) in ALK-positive NSCLC. It competes with ATP for binding to ALK, inhibiting its phosphorylation and downstream signaling, which results in decreased cell growth and survival in ALK-driven cancers. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor with activity against several kinases involved in tumor angiogenesis and signaling (VEGFR, PDGFR, RAF, among others). It disrupts pathways related to tumor growth, angiogenesis, and the tumor microenvironment. | ||||||